Biological Chemistry and Drug Discovery
David Gray has been promoted to Personal Chair. He takes the title of Professor of Translational Biology which is in recognition of his extensive work within the Drug Discovery Unit (DDU) and Wellcome Centre for Anti-Infectives Research (WCAIR).
The School of Life Sciences at the University of Dundee is a world-class academic institution with a reputation for the excellence of its research, its high quality teaching and student experience, and the strong impact of its activities outside academia. With 900 staff from over 60 countries worldwide the School provides a dynamic, multi-national, collegiate and diverse environment with state-of-the-art laboratory, technology and teaching facilities.
The Drug Discovery Unit (www.drugdiscovery.dundee.ac.uk) is a dynamic and multidisciplinary group of 95 scientists with expertise in structural biology, compound handling, assay development, high-throughput screening, medicinal and computational chemistry and in vitro and in vivo pharmacokinetics. The unit is housed in a state-of-the-art building and has cutting-edge equipment and automation, including an in-house X-ray diffractometer.
DEBRA is delighted to share that funding for a fourth year of the University of Dundee’s research into novel gene technology for treating Epidermolysis Bullosa (EB) has been agreed. £153,550 towards a total of £504,472 has been provided to enable the team lead by DEBRA Clinical Fellow, Dr Peter van den Akker (pictured), to develop two types of gene technology that can target genetic mutations caused by EB.
Two academic entrepreneurs from the division of Biological Chemistry and Drug Discovery have made the final of the Converge Challenge 2019. Andrew Woodland (In4Derm) and Michael Conneely (Ten Bio) will now go head-to-head against six other entrepreneurs leading both start-ups and spin-outs at the Converge Awards Final which takes place at the iconic V&A, Dundee later this month.
The University of Dundee’s Dr Sarah Coulthurst will lead a £2.7 million effort to investigate whether a ‘nanoweapon’ could be deployed in the global battle against antimicrobial resistance.
The World Health Organisation recently ranked antimicrobial resistance as one of the ten biggest threats to global health. As such, there is an urgent need to develop new treatments to prevent millions of lives being lost to diseases that are routinely treated with drugs such as antibiotics at present.
The Drug Discovery Unit (DDU) (http://www.drugdiscovery.dundee.ac.uk) is a fully integrated drug discovery operation based within a world class Life Sciences research environment. Its remit is to complement biopharma activities by tackling neglected diseases (leishmaniasis, TB and malaria) and validation of novel drug targets across a range of therapeutic areas. The DDU works to biotech style philosophy and standards incorporating, dynamic, goal driven project management based on Target Product Profiles and Compound Selection Criteria.